| [1] |
ZHANG Yan, CHEN Tongzhen, ZHU Xiaoli, LI Xiaoqiu.
Analysis of clinicopathological features of human papilloma virus-associated oropharyngeal squamous cell carcinoma
[J]. China Oncology, 2022, 32(1): 47-53.
|
| [2] |
XU Ran , WANG Xinyue , FENG Linyuan , HAN Anna , WANG Yixuan , YANG Wanshan , LIU Chao .
Expression and biological significance of NCAPD2 in glioma
[J]. China Oncology, 2021, 31(9): 789-798.
|
| [3] |
YANG Yanju, ZHONG Yang, HU Weigang, GAO Dadi, ZHAO Jun.
Effects of CT-RED calibration curves of different simulators on dose distribution of tumor target and organs at risk
[J]. China Oncology, 2021, 31(9): 828-837.
|
| [4] |
LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin.
The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer
[J]. China Oncology, 2021, 31(9): 838-844.
|
| [5] |
Tumor Support and Rehabilitation Therapy Group, the Oncology Committee of Chinese Medical Association.
Clinical practice guidelines for cancer-related fatigue in China (2021 edition)
[J]. China Oncology, 2021, 31(9): 852-872.
|
| [6] |
CONG Binbin, WANG Yongsheng.
Treatment landscape and challenges of managing the hormone receptor-positive early breast cancer
[J]. China Oncology, 2021, 31(8): 689-696.
|
| [7] |
ZHANG Yingqiang , LIN Yansong .
Application and research progress of 90 Y microspheres internal radiation therapy in colorectal cancer with liver metastasis
[J]. China Oncology, 2021, 31(8): 762-768.
|
| [8] |
XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia.
The advances in immunotherapy biomarkers of small cell lung cancer
[J]. China Oncology, 2021, 31(7): 635-639.
|
| [9] |
LI Wei, ZHANG Shanling, TAO Yingjie, WANG Xudong.
Research status and progress of mechanism of T cell immune metabolism and its application combined with immune checkpoint inhibitor
[J]. China Oncology, 2021, 31(7): 640-646.
|
| [10] |
NIU Na, LIN Yansong.
Application and research progress of selective internal radiation therapy with 90 Y microspheres in hepatocellular carcinoma
[J]. China Oncology, 2021, 31(5): 428-434.
|
| [11] |
ZHU Jun, WU Xiaohua.
Leading research progress and prospect of gynecological oncology in 2020
[J]. China Oncology, 2021, 31(4): 250-256.
|
| [12] |
ZHU Junjun, GE Naijian, YANG Yefa.
Current status and prospects of migration of radioactive 125 I seed implanted in malignant tumor
[J]. China Oncology, 2021, 31(4): 257-262.
|
| [13] |
ZHANG Jun , DONG Yuhua , YANG Ye , ZHANG Mengqi , HE Chang .
A novel strategy of regorafenib in combination with TAS102 against hepatocellular carcinoma
[J]. China Oncology, 2021, 31(4): 294-301.
|
| [14] |
CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin.
Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
[J]. China Oncology, 2021, 31(4): 330-334.
|
| [15] |
YU Li , SHEN Minna , JIANG Huiqin , WANG Beili , GUO Wei .
The progress and prospect of homologous recombination deficiency detection in clinical diagnosis and treatment of cancer
[J]. China Oncology, 2021, 31(4): 344-349.
|
